President And Ceo
CurrentTVAX Immunotherapy® is a novel autologous vaccine-enhanced adoptive T cell immunotherapy for cancer. This proprietary immunotherapy platform has demonstrated efficacy against several cancers with low toxicity, potentially offering a paradigm shift in the systemic treatment of cancer. Activated “killer” T cells have shown the ability to effectively treat numerous cancers without many of the undesirable side effects associated with radiation and chemotherapy. The key distinction between TVAX and other cancer immunotherapy companies is that TVAX Immunotherapy® uses both a cancer vaccine pre-treatment to generate cancer-specific T cells and an activated “killer” T cell treatment.